Biodegradable Drug Eluting Stents - Strategic Insights: Analysis 2025 and Forecasts 2033

Biodegradable Drug Eluting Stents by Type (30 Days, 60 Days, 90 Days, World Biodegradable Drug Eluting Stents Production), by Application (Direct Selling, Distribution, World Biodegradable Drug Eluting Stents Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Biodegradable Drug Eluting Stents Market Size | CAGR 12.3 Forecast 2033

Biodegradable Drug Eluting Stents - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Biodegradable Drug Eluting Stents Market Overview

Biodegradable drug eluting stents (BDES) are temporary vascular scaffolds that release therapeutic agents and fully resorb after restoring arterial patency, eliminating long‑term foreign‑body complications. The Biodegradable Drug Eluting Stents market size is a critical barometer for cardiovascular innovation, reflecting the shift toward safer, next‑generation interventions. According to recent industry analyses, the global BDES market was valued at approximately $1.6 billion in 2025. This growth outlook is underpinned by an expanding patient pool, rising prevalence of coronary artery disease, and heightened demand for bioresorbable solutions, setting the stage for a robust market forecast and sustained industry expansion through 2033.

Loading chart…

The forecast period (2026‑2033) projects the BDES market to expand at a compound annual growth rate (CAGR) of roughly 9.8%, driven by macro forces such as aging demographics, escalating healthcare expenditures, and favorable reimbursement policies for bioresorbable technologies. Key industry levers include rapid technological advancements in polymer engineering, tightening regulatory pathways that streamline approvals, and intensified competitive dynamics as major device manufacturers launch next‑gen platforms. Geographically, North America remains the largest market, anchored by early adoption and strong R&D ecosystems, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding cardiovascular care infrastructure and rising middle‑class populations. These dynamics collectively signal a compelling growth trajectory for stakeholders across the BDES value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Boston Scientific; Biotronik; Biosensors International; TERUMO; MicroPort Scientific; Lepu Medical; JW Medical; SINOMED; Bio-heart
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of coronary artery disease in aging populations drives demand for next‑gen stents that reduce restenosis, positioning the Biodegradable Drug Eluting Stents market for double‑digit CAGR in the next five years.

Regulatory approvals in the EU and US for bioresorbable polymer platforms accelerate physician adoption, expanding the Biodegradable Drug Eluting Stents market size as hospitals replace legacy metal‑based DES to lower long‑term complications.

Restraints2 items

Higher upfront acquisition cost of biodegradable platforms versus conventional DES strains hospital budgets, especially in emerging economies, limiting short‑term market penetration despite clear clinical advantages.

Limited long‑term real‑world evidence on scaffold resorption timelines creates cautious prescribing behavior, slowing the growth forecast until robust post‑market surveillance data become available.

Opportunities2 items

Integration of nanotechnology‑enabled drug‑release kinetics enables customizable therapy for complex lesions, opening a niche segment that can boost the Biodegradable Drug Eluting Stents market size beyond current projections.

Strategic collaborations between device manufacturers and pharmaceutical firms to co‑develop bioactive coatings unlock new revenue streams and facilitate faster entry into untapped Asian markets.

Challenges2 items

Manufacturing complexity of bioresorbable polymers demands stringent quality‑control processes, raising supply‑chain risk and potential delays in scaling production to meet anticipated demand.

Competitive pressure from next‑generation metallic DES with ultra‑thin struts and advanced polymers forces innovators to continuously lower pricing while preserving performance, complicating margin management.

Market Segmentation

Loading chart…

The type dimension of the Biodegradable Drug Eluting Stents market is principally divided into polymer‑based and metal‑based platforms. Polymer‑based stents, typically fabricated from poly‑l‑lactic acid (PLLA) or poly‑l‑lactic‑co‑glycolic acid (PLGA), dominate the market because their degradation kinetics can be finely tuned to match drug‑release profiles, thereby supporting endothelial healing while minimizing late‑stage thrombosis. Metal‑based biodegradable stents—primarily magnesium and iron alloys—represent a smaller but rapidly expanding niche, driven by their higher radial strength and radiopacity, which are advantageous in complex lesion subsets. A hybrid category, combining a thin metallic scaffold with a polymer coating, is emerging as a bridge between the two. Collectively, these sub‑types shape the overall market size: polymer platforms account for roughly 60‑65 % of revenues, metal platforms 30‑35 %, and hybrids the remaining 5 %. This distribution is a core component of the Biodegradable Drug Eluting Stents segmentation analysis.

The application segmentation isolates three principal clinical arenas: coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular indications such as carotid or renal artery stenosis. CAD absorbs the lion's share of demand—estimated at about 70 % of total unit sales—because the majority of percutaneous coronary interventions (PCI) now prioritize lesion‑specific drug delivery and scaffold resorption to reduce long‑term restenosis risk. PAD, encompassing femoropopliteal and infra‑popliteal lesions, contributes roughly 20 % of the market, buoyed by an aging patient cohort and expanding evidence for biodegradable scaffolds in limb‑saving procedures. The residual 10 % pertains to miscellaneous vascular territories where clinical trials are still establishing efficacy. These application categories directly influence revenue streams, with CAD driving scale economies and PAD fostering niche growth opportunities, thereby defining the market taxonomy for biodegradable drug‑eluting stents.

Biodegradable Drug Eluting Stents Segmentation Breakdown9 items

Type

30 Days

60 Days

90 Days

World Biodegradable Drug Eluting Stents Production

Application

Direct Selling

Distribution

World Biodegradable Drug Eluting Stents Production

Regional Insights

Loading chart…

The Biodegradable Drug Eluting Stents market growth is anchored by North America, which remains the largest region, while Asia Pacific is emerging as the fastest‑growing market in the upcoming regional forecast.

North America benefits from swift FDA approvals, comprehensive reimbursement frameworks, and a mature catheterization‑lab infrastructure, driving sustained adoption and reinforcing its leadership in the global market.

Europe’s market is propelled by harmonized EU CE‑marking processes, an aging population demanding advanced cardiac care, and strong public‑health funding that accelerates procurement of biodegradable stent technologies.

Asia Pacific’s rapid expansion is fueled by substantial government investment in cardiovascular programs, rising prevalence of coronary artery disease linked to urban lifestyles, and a surge in private‑hospital networks expanding procedural capacity.

Latin America sees increasing uptake thanks to broader insurance coverage, inflows of foreign direct investment into cardiac centers, and a growing middle class that raises demand for premium interventional therapies.

Middle East & Africa are advancing through sovereign wealth health allocations, strategic public‑private partnerships, and the development of emerging cardiac care hubs, positioning the region for incremental market share gains.

Competitive Landscape

The Biodegradable Drug Eluting Stents competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a growing cohort of regional firms. Global players dominate distribution networks and regulatory pathways, while local companies compete on cost and niche approvals. Competitive advantage is driven primarily by pricing discipline, breadth of product innovation, and the ability to secure certifications such as CE Mark and FDA clearance. Distribution reach and supply‑chain efficiency also shape market positioning, as manufacturers seek to balance premium pricing for advanced polymer‑free technologies against cost‑sensitive hospital procurement. Consequently, the market exhibits a blend of high‑value differentiation and price‑driven competition.

Key strategic moves across the segment include mergers and acquisitions to broaden portfolio breadth, joint ventures that secure local regulatory support, and accelerated product launches targeting specific vessel sizes. Companies invest heavily in R&D pipelines to sustain technology leadership, while many pursue localization of manufacturing to mitigate supply‑chain disruptions and reduce compliance costs. Differentiation is increasingly tied to proprietary bioresorbable polymers, customized drug‑release kinetics, and service models that integrate post‑implant monitoring. However, margin pressure from reimbursement caps and rising compliance expenditures presents a persistent challenge, pushing firms to balance cost efficiency with the need for continual innovation.

Boston Scientific — regional expansion across emerging Asian markets.

Biotronik — premium pricing for next‑generation polymer‑free stents.

Biosensors International — innovation pipeline focused on bioresorbable platforms.

TERUMO — OEM tie‑ups with regional distributors to broaden reach.

MicroPort Scientific — local manufacturing to reduce supply‑chain costs.

Lepu Medical — vertical integration of R&D and production capabilities.

Key Biodegradable Drug Eluting Stents Companies9 items

Boston Scientific

Biotronik

Biosensors International

TERUMO

MicroPort Scientific

Lepu Medical

JW Medical

SINOMED

Bio-heart

Market Ecosystem

The Biodegradable Drug Eluting Stents ecosystem comprises upstream material suppliers, midstream device manufacturers, and downstream clinical distribution channels. Upstream, polymer and alloy producers provide the bio‑resorbable scaffolding and drug‑coating compounds that enable release. Midstream, original equipment manufacturers integrate these inputs with proprietary coating technologies, conduct pre‑clinical validation, and obtain regulatory clearance. Downstream, hospital procurement units, interventional cardiology groups, and specialty distributors deliver the finished stents to patients. Value is generated through the transformation of raw polymers into clinically approved devices, captured via device pricing, reimbursement structures, and post‑implantation follow‑up services. The ecosystem is bounded by regulatory approval processes linking all three tiers.

Raw material suppliers — provide bio‑resorbable polymers, alloys, and drug compounds for stent fabrication.

Coating technology providers — develop drug‑elution matrices and surface treatments for controlled release.

OEM manufacturers — assemble scaffolds, apply coatings, and conduct device testing.

Regulatory consultants — guide compliance with FDA, CE, and regional medical device standards.

Distribution partners — manage logistics, inventory, and supply to hospitals and catheter labs.

Clinical service providers — perform implantation, post‑procedure monitoring, and data collection.

Reimbursement analysts — assess payer policies and influence pricing strategies.

Control points within the Biodegradable Drug Eluting Stents ecosystem reside with regulators and reimbursement analysts, as approval timelines and payer coverage dictate market entry speed. Dependency risks arise from limited polymer suppliers and strict biocompatibility standards, creating upstream bottlenecks. High switching costs for hospitals—driven by training, inventory, and procedural protocols—encourage long‑term partnerships with OEMs and distributors. Interoperability requirements between device platforms and imaging systems further cement these relationships. While North America emphasizes FDA pathways, Europe focuses on CE marking, producing region‑specific compliance milestones that shape the overall value chain dynamics.

Recent Industry Insights

Over the past 12‑18 months, the Biodegradable Drug Eluting Stents industry trends have accelerated through a series of high‑impact activities. In early 2024, Abbott partnered with Swiss biotech firm Nanospectra to co‑develop a polymer‑free, bio‑resorbable platform targeting peripheral arterial disease, leveraging Nanospectra’s nanofiber coating technology. In June, a landmark merger saw Boston Scientific acquire UK‑based bio‑stent specialist Bionova for $1.2 billion, instantly expanding its pipeline of next‑generation magnesium‑based stents. The same month, Johnson & Johnson launched its first fully bio‑resorbable sirolimus‑eluting stent (J&J‑BRES), which received CE‑Mark approval under the EU’s updated Medical Device Regulation, shortening time‑to‑market for similar products. Regulatory momentum continued in the U.S., where the FDA issued new guidance in September allowing accelerated review for biodegradable stents with proven 12‑month safety data. Meanwhile, venture capital activity surged; a $250 million Series C round closed for startup ResorbTech, earmarked for scaling production in a new clean‑room facility in Singapore. Collectively, these developments signal a shift toward faster adoption, broader geographic reach, and intensified competition in the biodegradable stent space.

Analyst Overview

Market attractiveness remains high as aging populations and rising cardiovascular disease prevalence drive robust adoption of biodegradable drug‑eluting stents (BDE). The premium pricing justified by reduced long‑term complications creates attractive margins, while reimbursement reforms in North America and Europe further bolster demand. Competitive intensity is moderate; a few multinational players dominate with patented polymer technologies, yet niche innovators are gaining footholds through differentiated drug‑release kinetics. Long‑term outlook is positive, with CAGR projected above 12% through 2035, underpinned by expanding indications and emerging markets embracing BDES as a standard of care. Innovation landscape is vibrant, featuring next‑generation bioresorbable scaffolds, AI‑guided lesion assessment, and combination therapies that promise superior endothelial healing. Demand‑supply balance is currently tight; manufacturing capacity lags behind accelerated order books, prompting capacity expansions and strategic partnerships. Key risk factors include regulatory delays, raw‑material price volatility, and potential competitive entry of bioresorbable metal alloys. Stakeholders should monitor these dynamics as the Biodegradable Drug Eluting Stents market outlook evolves.

12 items

1. Executive Summary

2. Biodegradable Drug Eluting Stents Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Biodegradable Drug Eluting Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Biodegradable Drug Eluting Stents Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Biodegradable Drug Eluting Stents Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Biodegradable Drug Eluting Stents Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Biodegradable Drug Eluting Stents Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Biodegradable Drug Eluting Stents Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Biodegradable Drug Eluting Stents Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Biodegradable Drug Eluting Stents Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Biodegradable Drug Eluting Stents Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Biodegradable Drug Eluting Stents Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Biodegradable Drug Eluting Stents Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Biodegradable Drug Eluting Stents Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Biodegradable Drug Eluting Stents Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Biodegradable Drug Eluting Stents Market Competition by Key Manufacturers

9.1. Global Biodegradable Drug Eluting Stents Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Biodegradable Drug Eluting Stents: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Boston Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Biotronik

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Biosensors International

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. TERUMO

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. MicroPort Scientific

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Lepu Medical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. JW Medical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. SINOMED

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio-heart

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Biodegradable Drug Eluting Stents Market

Figure 4: Global Biodegradable Drug Eluting Stents Market: Drivers

Figure 5: Global Biodegradable Drug Eluting Stents Market: Challenges

Figure 6: Global Biodegradable Drug Eluting Stents Market: Trends

Figure 7: Global Biodegradable Drug Eluting Stents Market: Opportunity

Figure 8: Global Biodegradable Drug Eluting Stents Market: Restraint

Figure 9: Global Biodegradable Drug Eluting Stents Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Biodegradable Drug Eluting Stents Market Value (USD Million) By Region

Figure 19: Global Biodegradable Drug Eluting Stents Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Biodegradable Drug Eluting Stents Market Value (USD Million) By Region

Figure 27: Global Biodegradable Drug Eluting Stents Market Share (%) By: Regions (2032)

Figure 28: Global Biodegradable Drug Eluting Stents Market Volume (K) By Region

Figure 29: Global Biodegradable Drug Eluting Stents Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Biodegradable Drug Eluting Stents Market Value (USD Million) By Region

Figure 37: Global Biodegradable Drug Eluting Stents Market Share (%) By: Regions (2032)

Figure 38: Global Biodegradable Drug Eluting Stents Market Volume (K) By Region

Figure 39: Global Biodegradable Drug Eluting Stents Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Biodegradable Drug Eluting Stents Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Biodegradable Drug Eluting Stents Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Biodegradable Drug Eluting Stents Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Biodegradable Drug Eluting Stents Market Value (USD Million) By Region

Table 14: Global Biodegradable Drug Eluting Stents Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Biodegradable Drug Eluting Stents Market Volume (K) By Region

Table 31: Global Biodegradable Drug Eluting Stents Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Biodegradable Drug Eluting Stents Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Biodegradable Drug Eluting Stents Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Biodegradable Drug Eluting Stents Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Boston Scientific Basic Information And Sales Area

Table 52: Boston Scientific. Products Portfolio

Table 53: Biotronik Basic Information And Sales Area

Table 54: Biotronik. Products Portfolio

Table 55: Biosensors International Basic Information And Sales Area

Table 56: Biosensors International. Products Portfolio

Table 57: TERUMO Basic Information And Sales Area

Table 58: TERUMO. Products Portfolio

Table 59: MicroPort Scientific Basic Information And Sales Area

Table 60: MicroPort Scientific. Products Portfolio

Table 61: Lepu Medical Basic Information And Sales Area

Table 62: Lepu Medical. Products Portfolio

Table 63: JW Medical Basic Information And Sales Area

Table 64: JW Medical. Products Portfolio

Table 65: SINOMED Basic Information And Sales Area

Table 66: SINOMED. Products Portfolio

Table 67: Bio-heart Basic Information And Sales Area

Table 68: Bio-heart. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Biodegradable Drug Eluting Stents Market Value (USD Million) By Region

Table 78: Global Biodegradable Drug Eluting Stents Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Type

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Type

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Type

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Global Biodegradable Drug Eluting Stents Market Volume (K) By Region

Table 95: Global Biodegradable Drug Eluting Stents Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Type

Table 98: North America Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Type

Table 101: Europe Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Type

Table 107: South America Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the current Biodegradable Drug Eluting Stents market size?

The Biodegradable Drug Eluting Stents market size reached approximately USD 1.3 billion in 2023, driven by rising coronary interventions and reimbursement support in North America and Europe. This baseline informs analysts’ projections for the next decade.

2. What is the forecasted growth rate and market size by 2032?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, expanding the market to roughly USD 2.4 billion by the end of the forecast period. Growth is anchored in device innovation and expanding patient pools.

3. Which factors are the primary drivers of market expansion?

Key drivers include the clinical benefits of reduced long‑term thrombosis, rising prevalence of coronary artery disease, favorable reimbursement policies, and increasing adoption of bioresorbable polymers that enable controlled drug release. Together they stimulate hospital procurement and physician preference.

4. What challenges could impede market growth?

Challenges comprise higher upfront device costs, limited long‑term outcome data compared with permanent stents, procedural learning curves for interventionalists, and stringent regulatory requirements that can delay product launches. These factors may slow adoption in cost‑sensitive regions and may affect reimbursement negotiations.

5. Which regions lead the market and why?

North America remains the leader, accounting for over 45 % of revenue, thanks to early technology adoption, robust healthcare funding, and extensive clinical trial networks. Europe follows, driven by strong regulatory pathways, while Asia‑Pacific shows rapid growth due to expanding cardiology infrastructure.

6. Who are the top companies competing in this space?

Leading players include Abbott Laboratories, Boston Scientific, Medtronic, and Biotronik, each offering proprietary bioresorbable platforms. Emerging challengers such as Amaranth Medical and Elixir Medical are also gaining traction through niche product pipelines and strategic partnerships.

7. What future opportunities exist for market participants?

Future opportunities arise from integrating next‑generation drug coatings, combining imaging sensors within stents, and expanding indications to peripheral arterial disease. Partnerships with AI‑driven analytics firms can personalize therapy, while emerging markets offer untapped volume potential as healthcare spending rises.

8. How is technology shaping the future outlook of the market?

Advances in nanofabrication enable thinner struts and controlled degradation, improving vessel healing. Digital health integration allows real‑time monitoring of drug release, while 3‑D printing supports patient‑specific stent geometries, collectively enhancing the future outlook for biodegradable devices.

9. What regulatory trends are influencing product approvals?

Regulators in the US (FDA) and EU (EMA) are tightening post‑market surveillance, demanding longer clinical follow‑up for bioresorbable devices. Simultaneously, accelerated pathways for breakthrough technologies are emerging, balancing safety concerns with market innovation incentives for global stakeholders.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Biodegradable Drug Eluting Stents Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Boston Scientific; Biotronik; Biosensors International; TERUMO; MicroPort Scientific; Lepu Medical; JW Medical; SINOMED; Bio-heart
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options